 Lexaria Bioscience Corp NASDAQ:LEXX CSE:LXX, a global innovator in drug delivery platforms, said Tuesday it will begin important new applied research and development study programs. In a statement, the company said the new study programs will target four-drug markets, including NSAIDs, nicotine replacement therapies, tetrahydrocannabinol THC, and erectile dysfunction. 